R&D News | pharmaphorum

News

FDA set to raise bar for clinical trials of CAR-T therapies

The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.

News

Lab-in-a-loop specialist Relation attracts Novartis alliance

UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.

News

FDA backs first AI tool for use in trials, targeting MASH

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with MASH to help measure disease activity.

News

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.

News

ASH: FDA okays Gamida aplastic anaemia therapy as data drops

The first cell therapy for severe aplastic anaemia – Gamida Cell's Omisirge – has been approved by the FDA.

News

ASH: Gilead preps filing for anito-cel on iMMagine-1 data

Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.

FDA set to raise bar for clinical trials of CAR-T therapies

Lab-in-a-loop specialist Relation attracts Novartis alliance

FDA backs first AI tool for use in trials, targeting MASH

ASH: Jaypirca matches Imbruvica in first-line CLL trial

ASH: FDA okays Gamida aplastic anaemia therapy as data drops

ASH: Gilead preps filing for anito-cel on iMMagine-1 data

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks